Therapeutic evaluation of the CXCR4-mAb in NSCLC and TNBC xenografts revealed that tumors with higher CXCR4 expression are more responsive to CXCR4-targeted therapy. The gene discussed is CXCR4; the disease is non-small cell lung carcinoma.